AU
UK
CA
NZ
IND
US
Last update at 2026-06-03T20:28:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Canadian Hidden Treasures And 2 More Small Caps With Strong Potential
Wed 24 Sep 25, 12:32 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.37643M | -4.15800M | -4.34100M | -11.52510M | -27.11429M |
| Minority interest | 0.01M | -0.11007M | 1.52M | 1.73M | 2.07M |
| Net income | -1.36327M | -4.26800M | -2.82500M | -5.31444M | -25.28834M |
| Selling general administrative | 1.64M | 1.46M | 4.37M | 7.87M | 7.70M |
| Selling and marketing expenses | - | - | 0.05M | 0.10M | 0.10M |
| Gross profit | 0.00000M | -0.25500M | 0.01M | 0.08M | 0.08M |
| Reconciled depreciation | 0.00000M | 0.31M | 1.13M | 1.21M | 1.19M |
| Ebit | - | -4.01105M | -10.60124M | -22.96303M | -19.06109M |
| Ebitda | -1.81753M | -3.75600M | -9.47624M | -21.75552M | -17.86851M |
| Depreciation and amortization | - | 0.26M | 1.12M | 1.21M | 1.19M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -1.81753M | -3.79600M | -10.60100M | -22.96303M | -19.06109M |
| Other operating expenses | 1.82M | 3.80M | 11.03M | 18.81M | 20.75M |
| Interest expense | 0.10M | 0.15M | 0.12M | 0.15M | 0.09M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 0.15M | - |
| Net interest income | -0.09571M | -0.14692M | -0.12115M | 0.15M | -0.09360M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | -1.51633M | -6.21066M | -1.82596M |
| Total revenue | 0.00000M | 0.00000M | 0.43M | 1.30M | 1.54M |
| Total operating expenses | 1.82M | 3.54M | 10.61M | 17.59M | 19.29M |
| Cost of revenue | 0.00000M | 0.26M | 0.42M | 1.22M | 1.46M |
| Total other income expense net | 0.44M | -0.36100M | 6.26M | 11.44M | -8.05321M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -1.37643M | -4.15774M | -4.34098M | -11.52510M | -27.11429M |
| Net income applicable to common shares | - | - | - | - | -25.04839M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Intangible assets | - | - | 0.15M | 0.75M | 0.88M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.14M | 0.08M | 0.40M | 4.88M | 0.65M |
| Total liab | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Total stockholder equity | 23.12M | 21.13M | 24.85M | 15.71M | 23.61M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.07M | 1.00M | 1.89M | 6.18M | 4.18M |
| Common stock | 0.00008M | 0.00006M | 0.00005M | 35.71M | 35.64M |
| Capital stock | 0.00008M | 0.00006M | 0.00005M | 35.71M | 35.64M |
| Retained earnings | -73.79280M | -72.42953M | -68.16172M | -65.33707M | -55.53751M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | 0.30M |
| Cash | 3.45M | 0.87M | 2.01M | 1.88M | 8.13M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.59M | 4.34M | 2.10M | 12.50M | 4.38M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 0.07M | 2.48M | 1.36M | 4.97M | -7.91405M |
| Short term debt | 3.52M | 3.34M | 0.20M | 6.32M | 0.19M |
| Short long term debt | 3.42M | 3.24M | - | 6.01M | - |
| Short long term debt total | 3.52M | 3.35M | 3.36M | 6.85M | 0.22M |
| Other stockholder equity | 97.00M | 93.47M | 93.02M | 45.31M | 43.51M |
| Property plant equipment | - | - | - | - | 3.89M |
| Total current assets | 3.59M | 0.96M | 2.48M | 7.07M | 12.69M |
| Long term investments | 15.10M | 15.10M | 16.10M | 9.74M | 4.16M |
| Net tangible assets | - | - | - | - | 22.73M |
| Short term investments | - | - | 0.00000M | 0.10M | 0.24M |
| Net receivables | - | 0.00455M | 0.07M | 1.41M | 3.63M |
| Long term debt | - | - | 3.06M | 0.50M | - |
| Inventory | - | - | 0.00000M | 0.03M | 0.04M |
| Accounts payable | - | - | - | - | 4.17M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.09231M | 0.09M | -0.01062M | 0.03M | -0.00202M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | 0.07M | 0.07M | 0.13M | 0.15M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 15.10M | 15.17M | 18.16M | 13.80M | 9.22M |
| Capital lease obligations | 0.02M | 0.12M | 0.22M | 0.34M | 0.22M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00000M | 0.06M | 0.62M | 2.44M | 20.12M |
| Change to liabilities | - | - | - | - | 0.86M |
| Total cashflows from investing activities | - | 0.06M | 0.62M | - | 16.51M |
| Net borrowings | 0.00000M | 0.00000M | 2.50M | - | -2.04351M |
| Total cash from financing activities | 4.41M | 0.00143M | 4.09M | 6.63M | 2.78M |
| Change to operating activities | - | - | - | - | 0.18M |
| Net income | -1.36327M | -4.26781M | -4.34098M | -11.52510M | -27.11429M |
| Change in cash | 2.58M | -1.13111M | -3.00753M | -3.24861M | 4.64M |
| Begin period cash flow | 0.87M | 2.01M | 5.01M | 8.26M | 3.63M |
| End period cash flow | 3.45M | 0.87M | 2.01M | 5.01M | 8.26M |
| Total cash from operating activities | -1.83608M | -1.19116M | -7.72436M | -12.31897M | -14.65163M |
| Issuance of capital stock | 5.07M | 0.00000M | 1.58M | 0.00536M | 4.00M |
| Depreciation | 0.00000M | 0.26M | 1.13M | 1.21M | 1.19M |
| Other cashflows from investing activities | - | - | 0.52M | - | -3.35809M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 0.00000M | 0.00000M | 0.01M | 0.00805M | 0.00336M |
| Change to account receivables | 0.00000M | 0.04M | 0.42M | -0.09570M | -0.01650M |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | - | - | -0.03802M | 6.67M | 4.32M |
| Change to netincome | - | - | - | - | 8.19M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00301M | 0.19M | 0.14M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -0.10284M | -0.21110M | 0.41M | 1.40M | 1.02M |
| Stock based compensation | 0.00000M | 0.00000M | 1.27M | 1.65M | 1.68M |
| Other non cash items | -0.36997M | 3.03M | -6.18090M | -5.04629M | 0.61M |
| Free cash flow | -1.83608M | -1.19116M | -7.72738M | -12.50588M | -14.78941M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| APM Aptorum Group Ltd Class A |
0.11 11.68% | 1.09 | - | - | 23.35 | 0.32 | 31.22 | -0.4545 |
| NVO Novo Nordisk A/S |
-0.92 2.14% | 42.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.38 0.89% | 42.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.25 0.76% | 428.34 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
16.03 2.66% | 618.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
17 Hanover Square, London, United Kingdom, W1S 1BN
| Name | Title | Year Born |
|---|---|---|
| Mr. Darren Lui | CEO, Chief Accounting Officer & Exec. Director | 1982 |
| Mr. Chung Yuen Huen | Founder & Non-Exec. Director | 1981 |
| Dr. Clark Cheng | Chief Medical Officer & Exec. Director | 1980 |
| Dr. Wai Yip Lee | Head of R&D | 1974 |
| Mr. Martin Siu | Head of Fin. | NA |
| Mr. Chung Yuen Huen | Founder, CEO & Non-Executive Director | 1980 |
| Mr. Martin Siu | Head of Finance | 1979 |
| Mr. Kwok Kuen Wong | Head of Finance | 1956 |
| Mr. Chung Yuen Huen | Founder, CEO & Executive Director | 1980 |
| Mr. Kwok Kuen Wong | Head of Finance | 1956 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...